K. Gessner

Quality of Life and Health State Utilities in Bladder Cancer

J. Gore, A. Deal, Angela B Smith, 2021, Bladder Cancer.

Implementation of Post-operative Standard Opioid Prescribing Schedules Reduces Opioid Prescriptions Without Change in Patient-Reported Pain Outcomes.

E. Wallen, A. Deal, M. Nielsen, 2020, Urology.

SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition

W. Rathmell, A. Lim, C. Walker, 2019, Oncotarget.

Genomic Meta-analysis of Clear-cell Renal Cell Carcinoma (ccRCC): Aggregating Tumors to Resolve the Complexity of ccRCC.

William Y. Kim, Ibardo Zambrano, K. Gessner, 2022, European urology.

Complete pathologic response to pembrolizumab and axitinib in a patient with sarcomatoid RCC and ocrelizumab-treated multiple sclerosis.

E. Wallen, S. Wobker, M. Bjurlin, 2021, Urology.

PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner

William Y. Kim, J. Simon, I. Davis, 2022, Cancer immunology research.

Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications.

Sara E. Wobker, Alysen L Demzik, K. Gessner, 2023, Cancer treatment and research communications.